fenofibrate has been researched along with Hyperprolactinemia in 1 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Hyperprolactinemia: Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because of concomitant atherogenic dyslipidemia, all patients were treated with fenofibrate (200 mg daily) for 12 weeks." | 7.91 | Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. ( Krysiak, R; Okopień, B; Szkróbka, W, 2019) |
| " Because of concomitant atherogenic dyslipidemia, all patients were treated with fenofibrate (200 mg daily) for 12 weeks." | 3.91 | Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. ( Krysiak, R; Okopień, B; Szkróbka, W, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krysiak, R | 1 |
| Szkróbka, W | 1 |
| Okopień, B | 1 |
1 other study available for fenofibrate and Hyperprolactinemia
| Article | Year |
|---|---|
Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Topics: Adult; Age Factors; Biomarkers; Bromocriptine; Cardiovascular Diseases; Case-Control Studies; Dopami | 2019 |